Chromium picolinate for insulin resistance in subjects with HIV disease: A pilot study

Diabetes, Obesity and Metabolism

Volumn 10, Issue 2, 2008, Pages 151-158

  Feiner, J J ^a   Mcnurlan, M A ^a   Ferris, R E ^a   Mynarcik, D C ^a   Gelato, M C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Chromium picolinate; Glucose clamp; Highly active antiretroviral therapy; HIV; Insulin resistance; Toxicity

Indexed keywords

ATORVASTATIN; CHROMIUM PICOLINATE; GLUCOSE; NUTRITION 21; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LEAN BODY WEIGHT; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

EID: 38049165851     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00681.x     Document Type: Article

References (40)

1. Lumpkin M. Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for the Treatment of Human Immunodeficiency Virus (HIV). FDA Public Health Advisory, Washington, DC, 1997.
2. Safrin S, Grunfeld, C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 2493-2505.
3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-2749.
4. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-977.
5. Haffner S, Meittinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-162.
6. Haffner S. Epidemiological studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Diabetes Care 1999; 22: C54-C56.
7. Barbaro G, Di Lorenzo G, Cirelli A et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25: 2405-2418.
8. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
9. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-F70.
10. Butt AA, Evans R, Skanderson M, Shakil AO. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol 2006; 44: 864-868.
11. Zenilman JM, Hook EW III, Shepherd M, Smith P, Rompalo AM, Celentano DD. Alcohol and other substance use in STD clinic patients: Relationships with STDs and prevalent HIV infection. Sex Transm Dis 1994; 21: 220-225.
12. Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 1786-1791.
13. Anderson R, Polansky M, Bryden N, Roginski E, Mertz W, Glinsmann W. Chromium supplementation of human subjects effects on glucose, insulin and lipid variables. Metab Clin Exp 1983; 32: 894-899.
14. Anderson R, Polansky M, Bryden N, Canary J. Supplemental chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low chromium diets. Am J Clin Nutr 1991; 54: 909-916.
15. Gurson CT, Saner G. Effect of chromium on glucose utilization in marasmic protein-calorie malnutrition. Am J Clin Nutr 1971; 24: 1313-1319.
16. Hopkins L, Ransome-Kute O, Majaj AS. Improvement of impaired carbohydrate metabolism by chromium 3 in malnourished infants. Am J Clin Nutr 1968; 21: 203-211.
17. Levine RA, Streeten DH, Doisy RJ. Effects of oral chromium supplementation on the glucose tolerance of elderly human subjects. Metabolism 1968; 17: 114-125.
18. Martinez O, MacDonald OC, Gibson RS, Bourn O. Dietary chromium and effect of chromium supplementation on glucose tolerance in elderly Canadian women. Nutr Res 1985; 5: 609-620.
19. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet Med 2000; 17: 684-685.
20. Potter JF, Levin P, Anderson RA, Freiberg JM, Andres R, Elahi D. Glucose metabolism in glucose-intolerant older people during chromium supplementation. Metabolism 1985; 34: 199-204.
21. Urberg M, Zemmel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism 1987; 36: 896-899.
22. Wilson B, Gondy A. Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. Diabetes Res Clin Pract 1995; 28: 179-184.
23. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 1980; 29: 919-925.
24. Nielsen F. Controversial chromium: Does the superstar mineral of the mountebanks receive appropriate attention from clinicians and nutritionists? Nutr Today 1996; 31: 226-233.
25. Wasser W, Geldman NS, D'Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate. Ann of Intern Med 1997; 126: 410.
26. Cerruli J, Grabe DW, Gauthier I, Malone M, MGoldrick MD. Chromium picolinate toxicity. Ann Pharmacother 1998; 32: 428-431.
27. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
28. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31: 514-520.
29. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312-321.
30. Wise SD, Nielsen MF, Cryer PE, Rizza RA. Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 2461-2469.
31. Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 1981; 30: 936-940.
32. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000; 284: 472-477.
33. Hepburn DD, Xiao J, Bindom S, Vincent JB, O'Donnell J. Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster. Proc Natl Acad Sci U S A 2003; 100: 3766-3771.
34. Stearns DM, Wise JP Sr, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. Faseb J 1995; 9: 1643-1648.
35. Gudi R, Slesinski RS, Clarke JJ, San RH. Chromium picolinate does not produce chromosome damage in CHO cells. Mutat Res 2005; 587: 140-6.
36. Witmer CM, Park HS, Shupack SI. Mutagenicity and disposition of chromium. Sci Total Environ 1989; 86: 131-148.
37. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27: 2741-51.
38. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 1998; 17: 548-555.
39. Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 439-458.
40. Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 1990; 152: 41-45.